Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15074996 | 0.85 | AOC2 (0.38) | MAPK14ALDH1A1FDPS | |
| SCHEMBL23374815 | 0.83 | P2RX3 (0.41) | MAPK14CA2ALDH1A1 | |
| SCHEMBL945863 | 0.83 | P2RX3 (0.41) | MAPK14CA2ALDH1A1 | |
| SCHEMBL944361 | 0.83 | P2RX3 (0.41) | MAPK14CA2ALDH1A1 | |
| SCHEMBL16447323 | 0.81 | MAPK14 (0.50) | MAPK14CA2 | |
| SCHEMBL15077466 | 0.81 | MAPK14 (0.50) | MAPK14CA2 | |
| SCHEMBL3598217 | 0.80 | APP (0.48) | MAPK14CA2ALDH1A1 | |
| SCHEMBL251926 | 0.80 | APP (0.48) | MAPK14CA2ALDH1A1 | |
| SCHEMBL382940 | 0.80 | APP (0.48) | MAPK14CA2ALDH1A1 | |
| SCHEMBL12673084 | 0.78 | ALDH1A1 (0.46) | MAPK14CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530452-B2 | Tricyclic boron compounds for antimicrobial therapy | MICURX PHARMACEUTICALS, INC. (KY) | 2013-09-10 | — | — | US | disclosed |
| US-8530452-B2 | Tricyclic boron compounds for antimicrobial therapy | MICURX PHARMACEUTICALS, INC. (KY) | 2013-09-10 | — | — | US | disclosed |
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | MICURX PHARMACEUTICALS, INC. (KY) | 2013-06-27 | — | — | US | disclosed |
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | MICURX PHARMACEUTICALS, INC. (KY) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | TBCA, TBCB, BTD | MAPK14 1350/4885CA2 2414/4885ALDH1A1 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.